L E Gaspar

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi Brain metastases in lung cancer
    Laurie E Gaspar
    University of Colorado Health Sciences Center, Department of Radiation Oncology, 1663 N Ursula Street, Box F 706, Suite 1032, Aurora, CO 80010 0510, USA
    Expert Rev Anticancer Ther 4:259-70. 2004
  2. ncbi Stereotactic body radiation therapy for lung tumors: system-related issues and complications
    Laurie E Gaspar
    Clin Lung Cancer 8:233. 2007
  3. ncbi A review of intensity-modulated radiation therapy
    Laurie E Gaspar
    University of Colorado Denver, Department of Radiation Oncology, Campus Mail Stop F 706, 1665 North Ursula Street, Suite 1032, P O Box 6510, Aurora, CO 80045, USA
    Curr Oncol Rep 10:294-9. 2008
  4. ncbi Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group
    Laurie E Gaspar
    MBA, University of Colorado Health Sciences Center, Department of Radiation Oncology, 1665 N Ursula St, Box F 706, Ste 1032, Aurora, CO 80010 0510, USA
    J Clin Oncol 23:2955-61. 2005
  5. ncbi Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base
    Laurie E Gaspar
    Department of Radiation Oncology, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045 0510, USA
    Clin Lung Cancer 6:355-60. 2005
  6. ncbi Optimizing chemoradiation therapy approaches to unresectable stage III non--small cell lung cancer
    L E Gaspar
    Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Curr Opin Oncol 13:110-5. 2001
  7. ncbi Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases
    L E Gaspar
    University of Colorado Health Science Center, Denver, CO, USA
    Int J Radiat Oncol Biol Phys 47:1001-6. 2000
  8. ncbi Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01?
    O E Streeter
    Department of Radiation Oncology, University of Southern California, Los Angeles 90033 0804, USA
    Int J Radiat Oncol Biol Phys 44:1047-52. 1999
  9. ncbi Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials
    J D Cox
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 43:505-9. 1999
  10. ncbi Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study
    Quynh Thu Le
    Department of Radiation Oncology, Stanford University, Stanford, California 94305 5847, USA
    Clin Cancer Res 10:5418-24. 2004

Detail Information

Publications46

  1. ncbi Brain metastases in lung cancer
    Laurie E Gaspar
    University of Colorado Health Sciences Center, Department of Radiation Oncology, 1663 N Ursula Street, Box F 706, Suite 1032, Aurora, CO 80010 0510, USA
    Expert Rev Anticancer Ther 4:259-70. 2004
    ..This article reviews the prognostic factors associated with brain metastases from lung cancer, as well as current treatment approaches with chemotherapy, surgery and radiation therapy...
  2. ncbi Stereotactic body radiation therapy for lung tumors: system-related issues and complications
    Laurie E Gaspar
    Clin Lung Cancer 8:233. 2007
  3. ncbi A review of intensity-modulated radiation therapy
    Laurie E Gaspar
    University of Colorado Denver, Department of Radiation Oncology, Campus Mail Stop F 706, 1665 North Ursula Street, Suite 1032, P O Box 6510, Aurora, CO 80045, USA
    Curr Oncol Rep 10:294-9. 2008
    ..As problems related to organ motion are increasingly addressed, the use of IMRT in the treatment of lung cancer, particularly in non-small cell lung cancer and mesothelioma, continues to rise...
  4. ncbi Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group
    Laurie E Gaspar
    MBA, University of Colorado Health Sciences Center, Department of Radiation Oncology, 1665 N Ursula St, Box F 706, Ste 1032, Aurora, CO 80010 0510, USA
    J Clin Oncol 23:2955-61. 2005
    ..CONCLUSION Brain metastases often develop early in the course of treatment for stage IIIA/B NSCLC. The statistical designs of ongoing trials of prophylactic cranial irradiation in stage III NSCLC have taken this into account...
  5. ncbi Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base
    Laurie E Gaspar
    Department of Radiation Oncology, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045 0510, USA
    Clin Lung Cancer 6:355-60. 2005
    ..These results demonstrate the continued need for the evaluation of new treatments in this group of patients...
  6. ncbi Optimizing chemoradiation therapy approaches to unresectable stage III non--small cell lung cancer
    L E Gaspar
    Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Curr Opin Oncol 13:110-5. 2001
    ..Alternative strategies may be required for poor-risk, elderly patients...
  7. ncbi Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases
    L E Gaspar
    University of Colorado Health Science Center, Denver, CO, USA
    Int J Radiat Oncol Biol Phys 47:1001-6. 2000
    ..An analysis of RTOG 91-04, a randomized study comparing two dose-fractionation schemes with a comparison to the established RTOG database, was considered important to validate the RPA classes...
  8. ncbi Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01?
    O E Streeter
    Department of Radiation Oncology, University of Southern California, Los Angeles 90033 0804, USA
    Int J Radiat Oncol Biol Phys 44:1047-52. 1999
    ....
  9. ncbi Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials
    J D Cox
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 43:505-9. 1999
    ..To evaluate the influence of cell type within non-small cell carcinoma of lung (NSCCL) on failure patterns when chemotherapy (CT) is combined with radiation therapy (RT)...
  10. ncbi Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study
    Quynh Thu Le
    Department of Radiation Oncology, Stanford University, Stanford, California 94305 5847, USA
    Clin Cancer Res 10:5418-24. 2004
    ..To determine the feasibility and a recommended phase II dose of tirapazamine when combined with chemoradiotherapy in limited-stage small cell lung cancer (LSCLC)...
  11. ncbi Prophylactic cranial irradiation for patients with lung cancer
    Thomas J Pugh
    Department of Radiation Oncology, University of Colorado at Denver Health Sciences Center, Aurora CO 80045 0510, USA
    Clin Lung Cancer 8:365-8. 2007
    ..Several important collaborative group trials are under way in an attempt to further define the role of PCI in patients with lung cancer...
  12. ncbi A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases
    Tracey E Schefter
    Department of Radiation Oncology, University of Colorado Health Sciences Center, Aurora, CO 80045 0510, USA
    Int J Radiat Oncol Biol Phys 62:1371-8. 2005
    ..To determine the maximum tolerated dose (MTD) of stereotactic body radiation therapy (SBRT) for liver metastases...
  13. ncbi A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas
    Amanda L Schwer
    Department of Radiation Oncology, University of Colorado Health Sciences Center, Aurora, CO 80045 0508, USA
    Int J Radiat Oncol Biol Phys 70:993-1001. 2008
    ..To determine the maximum tolerated dose (MTD) of fractionated stereotactic radiosurgery (SRS) with gefitinib in patients with recurrent malignant gliomas...
  14. ncbi Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy
    Robert McCammon
    Department of Radiation Oncology, University of Colorado Health Sciences Center, Aurora, CO, USA
    Int J Radiat Oncol Biol Phys 73:112-8. 2009
    ..To determine prognostic factors for local control of primary or metastatic tumors within the lung or liver treated with stereotactic body radiation therapy (SBRT) within a single institution...
  15. ncbi Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy
    Arthur K Liu
    Department of Radiation Oncology, University of Colorado Denver, Aurora, Colorado, USA
    Pediatr Blood Cancer 52:227-30. 2009
    ..We report on the incidence of vascular abnormalities seen in the children with craniopharyngioma who received radiation therapy at our institution...
  16. ncbi Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas
    Amanda L Schwer
    Department of Radiation Oncology, University of Colorado Denver, Aurora, CO 80045 0508, USA
    Int J Radiat Oncol Biol Phys 73:1352-7. 2009
    ..To describe the radiographic and histopathologic changes after stereotactic radiosurgery (SRS) and epidermal growth factor receptor inhibition in patients with recurrent malignant gliomas...
  17. ncbi Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases
    Kyle E Rusthoven
    University of Colorado Denver, Department of Radiation Oncology and Medical Oncology, Aurora, CO 80045, USA
    J Clin Oncol 27:1579-84. 2009
    ..To evaluate the efficacy and tolerability of high-dose stereotactic body radiation therapy (SBRT) for the treatment of patients with one to three lung metastases...
  18. ncbi Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases
    Kyle E Rusthoven
    University of Colorado Denver, Department of Radiation Oncology, Pathology, and Medical Oncology, Aurora, CO 80045, USA
    J Clin Oncol 27:1572-8. 2009
    ..To evaluate the efficacy and tolerability of high-dose stereotactic body radiation therapy (SBRT) for the treatment of patients with one to three hepatic metastases...
  19. ncbi Maximally safe resection followed by hypofractionated re-irradiation for locally recurrent ependymoma in children
    Arthur K Liu
    Department of Radiation Oncology, University of Colorado Denver, Aurora, Colorado 80045, USA
    Pediatr Blood Cancer 52:804-7. 2009
    ..To minimize the duration of therapy, we chose a hypofractionated regimen that has been shown to be well tolerated in adult patients...
  20. ncbi Surprised by stage III: unexpected N2 lymph node involvement found during surgery for early-stage NSCLC
    Scott A Kono
    Thoracic Oncology Program, University of Colorado Comprehensive Cancer Center, Denver, Colorado, USA
    Oncology (Williston Park) 23:424-9. 2009
    ....
  21. ncbi Interim analysis of a prospective phase I/II trial of SBRT for liver metastases
    Brian D Kavanagh
    Department of Radiation Oncology, University of Colorado, Aurora, Colorado 80045, USA
    Acta Oncol 45:848-55. 2006
    ..This interim analysis indicates that a very high rate of durable in-field tumor control can be safely achieved with SBRT to 1-3 liver lesions as administered in this protocol, to a prescription dose of 60 Gy in 3 fractions...
  22. ncbi Dosimetric comparison between 3DCRT and IMRT using different multileaf collimators in the treatment of brain tumors
    Meisong Ding
    Radiation Oncology Department, University of Colorado Health Science Center, Aurora, CO 80045, USA
    Med Dosim 34:1-8. 2009
    ..For relatively large and spherical brain tumors, the smaller collimator leaf widths give no significant benefit...
  23. ncbi Retrospective clinicopathologic correlation of gross tumor size of hepatocellular carcinoma: implications for stereotactic body radiotherapy
    Chris R Kelsey
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Am J Clin Oncol 28:576-80. 2005
    ..To determine the degree of correlation between radiographic size and true gross pathologic size for subjects with primary hepatocellular carcinoma (HCC)...
  24. ncbi Update in the treatment of brain metastases from lung cancer
    Amanda L Schwer
    University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Clin Lung Cancer 8:180-6. 2006
    ..This article reviews the clinical characteristics, prognostic factors, and treatment strategies of brain metastases from lung cancer with a particular emphasis on recent research developments in the field...
  25. ncbi Permanent 125iodine implants for recurrent malignant gliomas
    L E Gaspar
    Department of Radiation Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
    Int J Radiat Oncol Biol Phys 43:977-82. 1999
    ..To determine the efficacy and toxicity of permanent 125iodine implants for recurrent malignant gliomas...
  26. ncbi Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials
    Charles R Thomas
    Department of Radiation Oncology, The University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Int J Radiat Oncol Biol Phys 58:1405-10. 2004
    ....
  27. ncbi Swallowing function and weight change observed in a phase I/II study of external-beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 9207)
    L E Gaspar
    University of Colorado, Denver, USA
    Cancer J 7:388-94. 2001
    ..Ninety-two percent of patients were able to swallow at least liquids at some point after therapy. Future plans are to compare this with other cooperative group studies that utilized chemoradiation or surgery, without brachytherapy...
  28. ncbi Pulmonary sequelae after electron spinal irradiation
    T J Endicott
    Department of Radiation Oncology, Torrance Memorial Medical Center, 3330 Lomita Boulevard, Torrance, CA 90505, USA
    Radiother Oncol 60:267-72. 2001
    ..These changes were mild and predominantly asymptomatic...
  29. ncbi Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy
    C C Olsen
    Department of Radiation Oncology, University of Colorado, Denver, Aurora, CO 80045 000508, USA
    Int J Radiat Oncol Biol Phys 73:1414-24. 2009
    ..To describe the histologic and volumetric changes in normal liver tissue after stereotactic body radiotherapy (SBRT) for liver metastases...
  30. ncbi Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003
    Paul Okunieff
    Department of Radiation Oncology, JP Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Am J Clin Oncol 26:522-9. 2003
    ..This hypothesis is ready for testing in cancers of the breast, prostate, colon, and in sarcomas. Enlarging the therapeutic window is a major goal that would allow for an increasingly favorable therapeutic gain...
  31. ncbi The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
    Laurie E Gaspar
    Department of Radiation Oncology, University of Colorado Denver, Denver, CO, USA
    J Neurooncol 96:17-32. 2010
    ..Should patients with newly-diagnosed metastatic brain tumors undergo open surgical resection versus whole brain radiation therapy (WBRT) and/or other treatment modalities such as radiosurgery, and in what clinical settings?..
  32. ncbi Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023
    Karen Kelly
    University of Kansas Medical Center, Kansas City, KS 66160, USA
    J Clin Oncol 26:2450-6. 2008
    ..Early clinical studies with gefitinib showed promising efficacy and mild toxicity in patients with advanced non-small-cell lung cancer (NSCLC). Thus, gefitinib was an ideal agent to evaluate in a maintenance setting in stage III disease...
  33. ncbi Triple modality (neoadjuvant chemoradiotherapy followed by surgical resection): is it better than definitive chemoradiation therapy in cancer of the thoracic esophagus?
    Tracey E Schefter
    Int J Radiat Oncol Biol Phys 52:581-2. 2002
  34. ncbi Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712
    Angela M Davies
    University of California, Davis, Sacramento, CA, USA
    J Clin Oncol 24:5242-6. 2006
    ..This study evaluated adding consolidation paclitaxel after chemoradiotherapy for a similar patient cohort...
  35. ncbi Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504
    David R Gandara
    University of California, Davis Cancer Center, Sacramento, USA
    J Clin Oncol 21:2004-10. 2003
    ..Nevertheless, this study remains hypothesis-generating and does not provide definitive evidence of the benefit of this approach. Phase III trials evaluating the S9504 regimen have been initiated to validate these results...
  36. ncbi Patterns of surgical care of lung cancer patients
    Alex G Little
    Department of Surgery, Wright State University School of Medicine, Dayton, Ohio, USA
    Ann Thorac Surg 80:2051-6; discussion 2056. 2005
    ..This survey was performed to determine the patterns of surgical care provided patients with non-small cell lung carcinoma (NSCLC)...
  37. ncbi National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care
    Alex G Little
    Department of Surgery, Wright State University School of Medicine, 1 Wyoming St, Suite 7801 WCHE, Dayton, OH 45409, United States
    Lung Cancer 57:253-60. 2007
    ..To determine the epidemiology, pathology and patterns of care for patients with non-small cell lung cancer (NSCLC) in the United States...
  38. ncbi Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713
    Martin J Edelman
    Southwest Oncology Group (S9713, Operations Office, 14980 Omicron Drive, San Antonio, TX 78245-3217, USA
    J Clin Oncol 22:127-32. 2004
    ..This study and others which have tested paclitaxel in small-cell lung cancer dampens enthusiasm for this agent in the primary management of LSCLC...
  39. ncbi Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial
    Christina A Meyers
    Department of Neuro Oncology, Unit 431, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Clin Oncol 22:157-65. 2004
    ....
  40. ncbi Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy
    David R Gandara
    Department of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817 2229, USA
    Clin Lung Cancer 7:S93-7. 2005
    ..Herein, we review the rationale for a treatment paradigm employing consolidation docetaxel therapy after concurrent chemotherapy/RT and the results of recent clinical trials using this approach...
  41. ncbi Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504)
    David R Gandara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:116-21. 2006
    ..Survival outcomes were compared with a predecessor study (S9019) with identical eligibility, staging criteria, and treatment, excepting docetaxel consolidation...
  42. ncbi Patient demographics in HOG LUN 01-24 versus SWOG 9504: apples versus oranges?
    Laurie E Gaspar
    Clin Lung Cancer 8:466-7. 2007
  43. ncbi Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline
    Katherine M W Pisters
    M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 25:5506-18. 2007
    ..To determine the role of adjuvant chemotherapy and radiation therapy in patients with completely resected stage IA-IIIA non-small-cell lung cancer (NSCLC)...
  44. ncbi Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
    David W Andrews
    Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA
    Lancet 363:1665-72. 2004
    ..We aimed to assess whether stereotactic radiosurgery provided any therapeutic benefit in a randomised multi-institutional trial directed by the Radiation Therapy Oncology Group (RTOG)...
  45. ncbi Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer
    Lawrence H Einhorn
    Indiana Cancer Pavilion, Indianapolis, Indiana, USA
    J Thorac Oncol 3:545-55. 2008
  46. ncbi A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database
    Paul W Sperduto
    Minneapolis Radiation Oncology, Minneapolis, MN, USA
    Int J Radiat Oncol Biol Phys 70:510-4. 2008
    ..Treatment for brain metastases varies widely. A sound prognostic index is thus important to guide both clinical decision making and outcomes research...